Literature DB >> 8186985

Cardiovascular effects produced by micro-injection of angiotensin-(1-7) on vasopressor and vasodepressor sites of the ventrolateral medulla.

L C Silva1, M A Fontes, M J Campagnole-Santos, M C Khosla, R R Campos, P G Guertzenstein, R A Santos.   

Abstract

In this study, we determined the cardiovascular effects produced by micro-injection of the heptapeptide Angiotensin-(1-7) [Ang-(1-7)] into the rat ventrolateral medulla (VLM). Micro-injection of Ang-(1-7) into the rostral VLM and the caudal pressor area of the VLM produced significant increases in arterial pressure, comparable to that observed with micro-injection of Ang II. The changes in arterial pressure were associated with more variable changes in heart rate (HR) (usually tachycardia). On the other hand, micro-injection of Ang-(1-7) into the caudal depressor area induced decreases in arterial pressure and HR. The results suggest that, besides Ang II, Ang-(1-7) is involved in the mediation of the cardiovascular actions of the renin-angiotensin system in the VLM.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8186985     DOI: 10.1016/0006-8993(93)90920-i

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

2.  Angiotensin-(1-7) increases neuronal potassium current via a nitric oxide-dependent mechanism.

Authors:  Rui-Fang Yang; Jing-Xiang Yin; Yu-Long Li; Matthew C Zimmerman; Harold D Schultz
Journal:  Am J Physiol Cell Physiol       Date:  2010-10-27       Impact factor: 4.249

Review 3.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

4.  Central angiotensin (1-7) enhances baroreflex gain in conscious rabbits with heart failure.

Authors:  Sumit Kar; Lie Gao; Daniel A Belatti; Pamela L Curry; Irving H Zucker
Journal:  Hypertension       Date:  2011-08-15       Impact factor: 10.190

5.  Brain-selective overexpression of angiotensin-converting enzyme 2 attenuates sympathetic nerve activity and enhances baroreflex function in chronic heart failure.

Authors:  Liang Xiao; Lie Gao; Eric Lazartigues; Irving H Zucker
Journal:  Hypertension       Date:  2011-10-24       Impact factor: 10.190

Review 6.  Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure.

Authors:  Irving H Zucker; Harold D Schultz; Kaushik P Patel; Wei Wang; Lie Gao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

7.  Astroglia are a possible cellular substrate of angiotensin(1-7) effects in the rostral ventrolateral medulla.

Authors:  Fang Guo; Beihui Liu; Feige Tang; Samantha Lane; Ekaterina A Souslova; Dmitriy M Chudakov; Julian F R Paton; Sergey Kasparov
Journal:  Cardiovasc Res       Date:  2010-03-03       Impact factor: 10.787

Review 8.  Angiotensin-converting enzyme 2 in the brain: properties and future directions.

Authors:  Huijing Xia; Eric Lazartigues
Journal:  J Neurochem       Date:  2008-11-05       Impact factor: 5.372

9.  The pressor effect of angiotensin-(1-7) in the rat rostral ventrolateral medulla involves multiple peripheral mechanisms.

Authors:  Rita C Oliveira; Maria J Campagnole-Santos; Robson A S Santos
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

Review 10.  Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy.

Authors:  Christoph Schindler; Peter Bramlage; Wilhelm Kirch; Carlos M Ferrario
Journal:  Vasc Health Risk Manag       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.